Autres langues Beam Therapeutics Inc.

Actions

BEAM

US07373V1052

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
24,66 ^USD	+1,19%		-0,04%	-11,04%

09/09	Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01:00 PM
08/09	Transcript : Beam Therapeutics Inc. - Special Call

Autres langues

08/09	Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints
08/09	Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency
08/09	Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
01/09	Beam Therapeutics Inc. Appoints Eric Foster as Chief Commercial Officer
01/09	Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
31/08	Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
19/08	Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder
04/08	Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Earnings Flash (BEAM) Beam Therapeutics Posts Q2 Loss $1.18 a Share, vs. FactSet Est of $1.11 Loss
04/08	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $490,000, vs. FactSet Est of $16.4M
04/08	Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
23/07	Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
08/07	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise
08/07	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration
29/06	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 2000 Value Benchmark
29/06	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 3000E Value Benchmark
29/06	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 3000 Value Benchmark
29/06	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell Small Cap Comp Value Benchmark
29/06	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 2500 Value Benchmark
18/06	Beam Therapeutics Receives FDA Clearance for Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria
18/06	Beam Therapeutics Says FDA Clears Investigational New Drug Application for PKU Treatment
18/06	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
18/05	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
18/05	Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference
13/05	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference